IntelGenx Technologies’ (IGXT) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of IntelGenx Technologies (OTCMKTS:IGXT) in a research report released on Monday morning, AnalystRatings.com reports. HC Wainwright currently has a $1.00 target price on the stock.

A number of other research firms also recently issued reports on IGXT. Maxim Group restated a buy rating and set a $1.50 price objective on shares of IntelGenx Technologies in a report on Friday, August 9th. Zacks Investment Research downgraded shares of IntelGenx Technologies from a buy rating to a hold rating in a report on Wednesday, July 24th.

Shares of IGXT stock opened at $0.40 on Monday. The firm has a 50-day moving average of $0.48 and a 200-day moving average of $0.57. The company has a market cap of $37.41 million, a P/E ratio of -2.86 and a beta of 1.73. The company has a debt-to-equity ratio of 1.02, a current ratio of 4.08 and a quick ratio of 3.93. IntelGenx Technologies has a one year low of $0.39 and a one year high of $1.83.

IntelGenx Technologies (OTCMKTS:IGXT) last announced its earnings results on Thursday, August 8th. The company reported ($0.03) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.02) by ($0.01). The firm had revenue of $0.20 million during the quarter, compared to analysts’ expectations of $0.90 million. IntelGenx Technologies had a negative net margin of 541.77% and a negative return on equity of 175.02%. As a group, research analysts expect that IntelGenx Technologies will post -0.07 earnings per share for the current fiscal year.

About IntelGenx Technologies

IntelGenx Technologies Corp., a drug delivery company, focuses on the development of novel oral immediate-release and controlled-release products for the pharmaceutical market. It offers RIZAPORT, an oral thin film formulation of rizatriptan benzoate for the treatment of acute migraines. The company's products under development comprise INT0001/2004, an anti-hypertension drug; INT0004/2006, an antidepressant; INT0007/2006 for the treatment of erectile dysfunction; INT0008/2008 for migraine; INT0010/2006 for the treatment of neuropathic pain and nausea in cancer patients; INT0027/2011 to treat opioid dependence; INT0036/2013 for schizophrenia; and INT0043/2015 to treat Alzheimer's disease.

Read More: Net Income

Receive News & Ratings for IntelGenx Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IntelGenx Technologies and related companies with MarketBeat.com's FREE daily email newsletter.